Biotav uses the special properties of the Newcastle Disease Virus (NDV) to treat glioblastoma (GBM).

GBM is the most aggressive and common primary brain tumor in adults, with a median overall survival of 15 months.

Tumor recurrence and poor prognosis are associated with oncogenic stem cells (CSCs), which cause resistance to conventional therapies.

However, the Newcastle disease virus has been shown to selectively target and kill tumor cells based on defective interferon signaling in tumor tissue.

Results of early-phase in vivo studies with different NDV strains have already shown exciting results, with the combined therapy yielding significantly smaller tumor sizes and significantly longer median survival times.

Here at Biotav, we have developed a unique strain of NDV with an enhanced ability to cross the blood-brain barrier and selectively target tumor cells.

Working in collaboration with professors and doctors from several leading oncology departments in Israeli hospitals, we received a green light from the Israeli Ministry of Health to begin compassionate treatments, and then treat patients through the Hospital Exemption pathway.

In the future, we hope to develop an even more effective strain of NDV adapted to different types of tumors, in the hope of providing a gentler, safer, and better alternative to the conventional oncolytic treatments available today.